Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1999; 33:759-766
© 1999 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cohen-Solal, A.
Right arrow Articles by Merlet, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cohen-Solal, A.
Right arrow Articles by Merlet, P.

CLINICAL STUDIES

Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis

Alain Cohen-Solal, MD, PhD, FESC*, Yves Esanu, MD*, Damien Logeart, MD*, Fabienne Pessione, MD*, Claude Dubois, MD{dagger}, Gilles Dreyfus, MD{dagger}, René Gourgon, MD* and Pascal Merlet, MD, PhD{ddagger}

* Hôpitaux Beaujon, Clichy, France
{dagger} Foch, Suresnes, France
{ddagger} Centre Hospitalier Frederic Joliot, Orsay, France

Manuscript received May 19, 1998; revised manuscript received September 28, 1998, accepted November 5, 1998.

Reprint requests and correspondence: Pr. Alain Cohen-Solal, Service de Cardiologie, Hôpital Beaujon, 100 Boulevard du General Leclerc, 92110 Clichy, France
alain.cohen-solal{at}bjn.ap-hop-paris.fr

OBJECTIVES

This prospective study was undertaken to correlate early and late metaiodobenzylguanidine (MIBG) cardiac uptake with cardiac hemodynamics and exercise capacity in patients with heart failure and to compare their prognostic values with that of peak oxygen uptake (VO2).

BACKGROUND

The cardiac fixation of MIBG reflects presynaptic uptake and is reduced in heart failure. Whether it is related to exercise capacity and has better prognostic value than peak VO2 is unknown.

METHODS

Ninety-three patients with heart failure (ejection fraction <45%) were studied with planar MIBG imaging, cardiopulmonary exercise tests and hemodynamics (n = 44). Early (20 min) and late (4 h) MIBG acquisition, as well as their ratio (washout, WO) were determined. Prognostic value was assessed by survival curves (Kaplan–Meier method) and uni- and multivariate Cox analyses.

RESULTS

Late cardiac MIBG uptake was reduced (131 ± 20%, normal values 192 ± 42%) and correlated with ejection fraction (r = 0.49), cardiac index (r = 0.40) and pulmonary wedge pressure (r = –0.35). There was a significant correlation between peak VO2 and MIBG uptake (r = 0.41, p < 0.0001). With a mean follow-up of 10 ± 8 months, both late MIBG uptake (p = 0.04) and peak VO2 (p < 0.0001) were predictive of death or heart transplantation, but only peak VO2 emerged by multivariate analysis. Neither early MIBG uptake nor WO yielded significant insights beyond those provided by late MIBG uptake.

CONCLUSIONS

Metaiodobenzylguanidine uptake has prognostic value in patients with wide ranges of heart failure, but peak VO2 remains the most powerful prognostic index.

Abbreviations and Acronyms
  CHF = chronic heart failure
  EF = ejection fraction
  H/M = heart/mediastinum
  MIBG = metaiodobenzylguanidine
  NYHA = New York Heart Association
  ROC = receiver operating characteristic
  VO2 = oxygen uptake
  WO = wash-out




This article has been cited by other articles:


Home page
Eur Heart JHome page
H. J. Verberne, L. M. Brewster, G. A. Somsen, and B. L.F. van Eck-Smit
Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review
Eur. Heart J., May 1, 2008; 29(9): 1147 - 1159.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
H. Kioka, T. Yamada, T. Mine, T. Morita, Y. Tsukamoto, S. Tamaki, M. Masuda, K. Okuda, M. Hori, and M. Fukunami
Prediction of sudden death in patients with mild-to-moderate chronic heart failure by using cardiac iodine-123 metaiodobenzylguanidine imaging
Heart, October 1, 2007; 93(10): 1213 - 1218.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
P. A. Gould, G. Kong, V. Kalff, S. J. Duffy, A. J. Taylor, M. J. Kelly, and D. M. Kaye
Improvement in cardiac adrenergic function post biventricular pacing for heart failure
Europace, September 1, 2007; 9(9): 751 - 756.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
A. Cohen-Solal, F. Rouzet, A. Berdeaux, D. Le Guludec, E. Abergel, A. Syrota, and P. Merlet
Effects of Carvedilol on Myocardial Sympathetic Innervation in Patients with Chronic Heart Failure
J. Nucl. Med., November 1, 2005; 46(11): 1796 - 1803.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
M. Sato, K. Maehara, H. Yaoita, H. Otani, A. Hirosaka, T. Saito, N. Onuki, N. Komatsu, T. Ishihata, and Y. Maruyama
Correlation Between Cardiac Norepinephrine Overflow During Exercise and Cardiac 123I-MIBG Uptake in Patients with Chronic Heart Failure
J. Nucl. Med., October 1, 2003; 44(10): 1618 - 1624.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
A. Muxi, J. Magrina, F. Martin, M. Josa, D. Fuster, F. J. Setoain, F. Perez-Villa, J. Pavia, and X. Bosch
Technetium 99m-labeled tetrofosmin and iodine 123-labeled metaiodobenzylguanidine scintigraphy in the assessment of transmyocardial laser revascularization
J. Thorac. Cardiovasc. Surg., June 1, 2003; 125(6): 1493 - 1498.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
T. Yamada, T. Shimonagata, M. Fukunami, K. Kumagai, H. Ogita, A. Hirata, M. Asai, N. Makino, H. Kioka, H. Kusuoka, et al.
Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: A prospective study
J. Am. Coll. Cardiol., January 15, 2003; 41(2): 231 - 238.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
P. Jourdain, F. Funck, Y. Fulla, A. Hagege, M. Bellorini, N. Guillard, J. Loiret, B. Thebault, and M. Desnos
Myocardial contractile reserve under low doses of dobutamine and improvement of left ventricular ejection fraction with treatment by carvedilol
Eur J Heart Fail, June 1, 2002; 4(3): 269 - 276.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
A. Cohen-Solal, J.Y. Tabet, D. Logeart, P. Bourgoin, M. Tokmakova, and M. Dahan
A non-invasively determined surrogate of cardiac power ('circulatory power') at peak exercise is a powerful prognostic factor in chronic heart failure
Eur. Heart J., May 2, 2002; 23(10): 806 - 814.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
P. Merlet, L. Hittinger, J. L. Dubois-Rande, and A. Castaigne
Myocardial Adrenergic Dysinnervation in Dilated Cardiomyopathy: Cornerstone or Epiphenomenon?
J. Nucl. Med., April 1, 2002; 43(4): 536 - 539.
[Full Text] [PDF]


Home page
JNMHome page
M. Shimizu, H. Ino, M. Yamaguchi, H. Terai, K. Hayashi, K. Nakajima, J. Taki, and H. Mabuchi
Heterogeneity of Cardiac Sympathetic Nerve Activity and Systolic Dysfunction in Patients with Hypertrophic Cardiomyopathy
J. Nucl. Med., January 1, 2002; 43(1): 15 - 20.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
H Ogita, T Shimonagata, M Fukunami, K Kumagai, T Yamada, Y Asano, A Hirata, M Asai, H Kusuoka, M Hori, et al.
Prognostic significance of cardiac 123I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study
Heart, December 1, 2001; 86(6): 656 - 660.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
T. Wakabayashi, T. Nakata, A. Hashimoto, S. Yuda, K. Tsuchihashi, M. I. Travin, and K. Shimamoto
Assessment of Underlying Etiology and Cardiac Sympathetic Innervation to Identify Patients at High Risk of Cardiac Death
J. Nucl. Med., December 1, 2001; 42(12): 1757 - 1767.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
P. A.R. de Milliano, B. L.F. van Eck-Smit, P. A. van Zwieten, A. C. de Groot, J. G.P. Tijssen, and K. I. Lie
Relationship between cardiac metaiodobenzylguanidine uptake and hemodynamic, functional and neurohormonal parameters in patients with heart failure
Eur J Heart Fail, December 1, 2001; 3(6): 693 - 697.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
I. Carrio
Cardiac Neurotransmission Imaging
J. Nucl. Med., July 1, 2001; 42(7): 1062 - 1076.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
P Acar, P Merlet, L Iserin, D Bonnet, D Sidi, A Syrota, and J Kachaner
Impaired cardiac adrenergic innervation assessed by MIBG imaging as a predictor of treatment response in childhood dilated cardiomyopathy
Heart, June 1, 2001; 85(6): 692 - 696.
[Abstract] [Full Text]


Home page
Eur Heart JHome page
J.-Y. Tabet, D. Logeart, C. Geyer, C. Guiti, P.V. Ennezat, M. Dahan, and A. Cohen-Solal
Comparison of the prognostic value of left ventricular filling and peak oxygen uptake in patients with systolic heart failure
Eur. Heart J., November 2, 2000; 21(22): 1864 - 1871.
[Abstract] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement